Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8664231 | MEDEXUS | Concentrated methotrexate solutions |
Jun, 2029
(5 years from now) |
Rasuvo is owned by Medexus.
Rasuvo contains Methotrexate.
Rasuvo has a total of 1 drug patent out of which 0 drug patents have expired.
Rasuvo was authorised for market use on 10 July, 2014.
Rasuvo is available in solution;subcutaneous dosage forms.
Rasuvo can be used as subcutaneous injection of methotrexate.
The generics of Rasuvo are possible to be released after 01 June, 2029.
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 10 July, 2014
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION;SUBCUTANEOUS